William Bonificio, Ph.D.

Bill is an experienced business development professional with broad experience in drug development, investor relations, and corporate operations.  He previously served as the Chief Business Officer of Tenet Medicines prior to its acquisition by Eliem. He has served as Chief Business or Strategy Officer at a number of companies, including ValenzaBio, where he helped to successfully in-license 3 antibody programs, leading to its acquisition by ACELYRIN, Inc. in 2023.  Prior to that Bill spent time as a biotech analyst at multiple investment funds.

Dr Bonificio has a Ph.D. in Applied Physics from Harvard University.